Alembic Pharma Q4 Results: US business grows 20%, strong growth in India branded division

Alembic Pharmaceuticals reported a mixed set of numbers for the March quarter, with a drop in profitability despite healthy top-line growth. The company’s consolidated net profit fell 11.8% year-on-year to ₹157 crore, compared to ₹178 crore in the same quarter last year.

Revenue, however, rose 16.7% to ₹1,769.6 crore from ₹1,517 crore in Q4 FY24, ahead of estimates that had pegged growth around 8%.

Operating performance remained steady, with EBITDA increasing 4.6% to ₹272 crore against ₹260 crore in the year-ago period. EBITDA margin, however, narrowed to 15.4% from 17.1% a year earlier.

On a segmental basis, the India branded business rose 8% in Q4 to ₹545 crore, led by strength in specialty therapies. The US generics business grew 20% to ₹508 crore, while ex-US markets jumped 43% to ₹375 crore. The API segment saw modest growth of 4% to ₹342 crore.

Management said strong momentum in domestic and international markets, particularly in the animal health and ex-US segments, sets a “solid foundation for future growth.” FY25 earnings per share stood at ₹29.68.

Vedant Fashions Q4 Results: Stock falls over 5% on muted earnings; ₹8 dividend proposed

The Board of Directors recommended a dividend of ₹11 per share for the financial year FY25, subject to shareholder approval at the upcoming AGM.

Shares of Alembic Pharma reacted negatively post the results, falling as much as 4.4% to an intraday low of ₹864.10 on the BSE, compared to the previous close of ₹903.90.